Abstract
OBJECTIVES:
Treatment
for ovarian cancer with bevacizumab(Bmab)has been covered by public
medical insurance in Japan since November 2013. It is recommended that
the use of Bmab is limited to the first treatment for FIGO stage III or
IV ovarian cancer. The OCEAN trial for platinum sensitivity in relapsed
patients and the AURELIA trial for platinum-resistance in relapsed
patients were performed, and both significantly improved
progression-free survival.
METHOD:
We
retrospectively studied patients receiving Bmab with an anticancer
agent for recurrent ovarian cancer. Written informed consent was
obtained from all patients.
RESULTS:
Between
November 2013 and September 2015, Bmab at 15mg/kg/3-4 week was
administered to 20 patients with recurrent ovarian cancer. The median
age was 58 years(range 32-81)and the median performance status was 0-2.
Platinum-sensitive recurrence occurred in 6 patients. The response rate
and disease control rate of combination chemotherapy with Bmab was 50.0%
and 57.1%. However, 11 patients stopped treatment with Bmab due to
serious adverse events.
CONCLUSION:
Combination chemotherapy with Bmab for recurrent ovarian cancer may be feasible.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.